Across TCGA pan-cancer cohorts, DCDC2B mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of DCDC2B’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where DCDC2B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types DCDC2B is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD and LSCC are the cancer types where DCDC2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DCDC2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	−0.861	<.001	9	view →
LSCC	All	All	−0.737	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: DCDC2B RNA expression & survival · all DCDC2B data types